Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study

Roberts, Matthew A., Pilmore, Helen L., Lerino, Francesco L., Badve, Sunil V., Cass, Alan, Garg, Amit X., Hawley, Carmel M., Isbel, Nicole M., Krum, Henry, Pascoe, Elaine M., Tonkin, Andrew M., Vergara, Liza, Perkovic, Vlado and BLOCADE Study Collaborative Group (2015). The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study. Nephrology,20(3):140-147.

Document type: Journal Article
Citation counts:
Google Scholar Search Google Scholar

IRMA ID 11381xPUB23
Title The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study
Author Roberts, Matthew A.
Pilmore, Helen L.
Lerino, Francesco L.
Badve, Sunil V.
Cass, Alan
Garg, Amit X.
Hawley, Carmel M.
Isbel, Nicole M.
Krum, Henry
Pascoe, Elaine M.
Tonkin, Andrew M.
Vergara, Liza
Perkovic, Vlado
BLOCADE Study Collaborative Group
Journal Name Nephrology
Publication Date 2015
Volume Number 20
Issue Number 3
ISSN 1320-5358   (check CDU catalogue  open catalogue search in new window)
Scopus ID 2-s2.0-84923374430
Start Page 140
End Page 147
Total Pages 8
Place of Publication Australia
Publisher Wiley-Blackwell Publishing Asia
Field of Research 1102 - Cardiovascular Medicine and Haematology
HERDC Category C1 - Journal Article (DIISR)
Abstract Aims
The Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study aims to determine the feasibility of a large-scale randomized controlled trial with clinical endpoints comparing the beta-blocking agent carvedilol with placebo in patients receiving dialysis.

Methods

The BLOCADE Feasibility Study is a randomized, double-blind, placebo-controlled, parallel group feasibility study comparing the beta-blocking agent carvedilol with placebo. Patients receiving dialysis for ≥3 months and who are aged ≥50 years, or who are ≥18 years and have diabetes or cardiovascular disease, were eligible. The primary outcome was the proportion of participants who complete a 6-week run-in phase in which all participants received carvedilol titrated from 3.125 mg twice daily to 6.25 mg twice daily. Other measures included how many patients are screened, the proportion recruited, the overall recruitment rate, the proportion of participants who remain on study drug for 12 months and the incidence of intra-dialytic hypotension while on randomized treatment.

Results

The BLOCADE Feasibility Study commenced recruiting in May 2011 and involves 11 sites in Australia and New Zealand.

Conclusions

The BLOCADE Feasibility Study will inform the design of a larger clinical endpoint study to determine whether beta-blocking agents provide benefit to patients receiving dialysis, and define whether such a study is feasible.
DOI http://dx.doi.org/10.1111/nep.12362   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 4 Abstract Views  -  Detailed Statistics
Created: Tue, 26 Jul 2016, 12:45:11 CST